Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 2/20 | 0.39 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4972908 | 0.97 | ALDH1A1 (0.41) | SPPL2AALDH1A1LMNAGAAMAPT | |
| SCHEMBL4975302 | 0.95 | SPPL2A (0.41) | SPPL2AMEP1BALDH1A1LMNAGAA | |
| SCHEMBL5024921 | 0.92 | ALDH1A1 (0.43) | SPPL2AALDH1A1LMNAGAAMAPT | |
| SCHEMBL4971626 | 0.91 | SPPL2A (0.40) | SPPL2AMEP1BALDH1A1LMNAGAA | |
| SCHEMBL5026601 | 0.91 | SPPL2A (0.38) | SPPL2ALMNA | |
| SCHEMBL6741163 | 0.91 | MEP1B (0.40) | SPPL2AMEP1BALDH1A1LMNAGAA | |
| Hydrochloric Acid SCHEMBL4972693 | 0.90 | MEP1B (0.39) | SPPL2AMEP1BALDH1A1LMNAGAA | |
| SCHEMBL4972243 | 0.90 | SPPL2A (0.41) | SPPL2AMEP1BALDH1A1LMNAGAA | |
| SCHEMBL4973879 | 0.89 | SPPL2A (0.40) | SPPL2ALMNA | |
| SCHEMBL4973342 | 0.89 | SPPL2A (0.41) | SPPL2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030204097-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-10-30 | — | — | US | claimed |
| US-6316496-B1 | FOR THERAPY OF RETROVIRAL INFECTION; PROPHYLAXIS OF REPLICATION OF RETROVIRUS, THERAPY OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | G. D. SEARLE & CO. | 2001-11-13 | — | — | US | claimed |
| US-20080118969-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE LLC (US) | 2008-05-22 | — | — | US | disclosed |
| US-7339078-B2 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070037754-A1 | Inhibitors of HIV protease; 2S-[[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide | G.D. SEARLE & CO. (US) | 2007-02-15 | — | — | US | disclosed |
| US-7161033-B2 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050227926-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-10-13 | — | — | US | disclosed |
| US-6861539-B1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2005-03-01 | — | — | US | disclosed |
| US-6683210-B2 | HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS, HUMAN IMMUNODEFICIENCY VIRUS, AND LYMPHADENOPATHY ASSOCIATED VIRUS TREATMENT | G. D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| US-20030204097-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-10-30 | — | — | US | disclosed |
| US-6388132-B1 | AIDS THERAPY | G. D. SEARLE & CO. | 2002-05-14 | — | — | US | disclosed |
| US-6316496-B1 | FOR THERAPY OF RETROVIRAL INFECTION; PROPHYLAXIS OF REPLICATION OF RETROVIRUS, THERAPY OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | G. D. SEARLE & CO. | 2001-11-13 | — | — | US | disclosed |
| EP-1076062-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2001-02-14 | — | — | EP | disclosed |
| US-6150556-A | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) PROTEASE; PROPHYLAXIS AND THERAPY OF RETROVIRUS INFECTIONS | G. D. DEARLE & CO. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6143788-A | ENZYME INHIBITORS | G.D. SEARLE & CO. (US) | 2000-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037754-A1 | Inhibitors of HIV protease; 2S-[[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide | DNPEP, PREP, ANPEP | SPPL2A 197/4885MEP1B 305/4885ALDH1A1 1286/4885 |
| US-20050227926-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | SPPL2A 654/4885MEP1B 304/4885ALDH1A1 3909/4885 |
| US-20030204097-A1 | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, PRSS1 | SPPL2A 654/4885MEP1B 304/4885ALDH1A1 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.